Median age (range), years |
61.5 (38-81) |
Sex, n (%) |
|
Female |
15 (46.9) |
Male |
17 (53.1) |
Race, n (%) |
|
White |
30 (93.8) |
Unknown |
2 (6.3) |
ECOG performance status, n (%) |
|
0 |
8 (25.0) |
1 |
24 (75.0) |
Primary site of cancer, n (%) |
|
Colon |
10 (31.3) |
Lung |
8 (25.0) |
Esophagus |
2 (6.3) |
Oral cavity |
2 (6.3) |
Pancreas |
2 (6.3) |
Rectum |
2 (6.3) |
Bladder |
1 (3.1) |
Duodenum |
1 (3.1) |
Kidney |
1 (3.1) |
Skin melanoma |
1 (3.1) |
Small intestine |
1 (3.1) |
Uterus |
1 (3.1) |
Stage at study entry, n (%) |
|
III |
1 (3.1) |
IIIB |
2 (6.3) |
IV |
27 (84.4) |
IVB |
2 (6.3) |
Type of lesion per investigator assessment at baseline, n (%) |
|
Both target and non-target |
22 (68.8) |
Target only |
10 (31.3) |
Number of metastatic sites of cancer, median (range) |
3
(1-7) |
MET dysregulation
|
|
MET overexpression |
24 (75) |
MET amplification |
14 (43.8) |
MET mutation |
3 (9.4) |
Prior anti-cancer medications, n (%) |
|
Any |
32 (100) |
Chemotherapy |
31 (96.9) |
Surgery |
17 (53.1) |
Radiotherapy |
14 (43.8) |
Number of prior chemotherapy regimens, n (%) |
|
1 |
3 ( 9.4) |
2 |
11 (34.4) |
3 |
3 ( 9.4) |
≥4 |
15 (46.9) |
Type of last therapy, n (%) |
|
Chemotherapy |
19 (59.4) |
Targeted therapy |
7 (21.9) |
Radiotherapy |
3 (9.4) |
Surgery |
5 (15.6) |
Other |
6 (18.8) |
Best response to last therapya, n (%) |
|
Stable disease |
3 (9.4) |
Progressive disease |
21 (65.6) |
Not applicable |
14 (43.8) |
Unknown |
2 (6.3) |